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Introduction. Operative blood loss is still a great obstacle to liver resection, and various topical hemostatic agents were introduced
to reduce it. The aim of the current study is to evaluate effects of 3 different types of these agents. Methods. In this randomized
clinical trial, 45 patients undergoing liver resection were assigned to receive TachoSil, Surgicel, and Glubran 2 for controlling
bleeding. Intraoperative and postoperative findingswere compared between groups.Results. Postoperative bleeding (0 versus 33.3%,
𝑃 = 0.04) and drainage volume first day after surgery (281.33 ± 103.98 versus 150.00 ± 60.82mL, 𝑃 = 0.02) were significantly
higher in Surgicel than in TachoSil group. Postoperative complications included bile leak (3 cases in Surgicel, 1 case in TachoSil and
Glubran 2), noninfectious collection (2 cases in TachoSil and Surgicel and 1 case in Glubran 2), perihepatic abscess, and massive
hematoma around hepatectomy site both in Surgicel group.There was no death during the study period. Conclusion. Due to higher
complications in Surgicel group, its application as hemostatic agent after liver resection is not recommended. Better results in
TachoSil in comparison to the other two are indicative of its better efficacy and superiority in controlling hemostasis.
1. Introduction
Advances in surgical technique have reduced the occurrence
of postoperative complications following liver resection [1]
and resulted in low surgical mortality and morbidity rates in
high-volume centers [2–4]. Surgical techniques and devices
to facilitate haemostasis have been developed in the last
decades and haveminimized operative risks of liver resection
[1, 2].
During liver resection, the control of bleeding is a major
concern. Despite the improvements in anatomic resection
and dissection techniques, operative blood loss remains a
major problem affecting the prognosis of patients undergoing
liver resection [2, 5]. Nevertheless, a parenchymal transection
of the liver tissue is always associated with some degree of
bleeding due to the division of small blood vessels which
cannot be isolated and ligated [6, 7].
In order to control diffuse bleeding and to prevent
intraperitoneal complications attributed to bleeding, various
topical products are used when the conventional methods,
such as suture, ligation, or argon beam coagulation, fail.
Currently, there are numerous products on the market which
are promising a successful outcome for hemostasis. These
products include gelatin, collagen, oxidized regenerated cel-
lulose, fibrin sealant glues, and synthetic glues [7–11].
TachoSil (fibrin sealant glue) and Surgicel (cellulose based
hemostat) are among those with considerable success [11].
Glubran 2 (synthetic cyanoacrylate glue) is a newly developed
agent with promising results in various surgeries [12, 13]. Due
to its success, it is possible to be used as a hemostatic agent
in liver resection. These products have various differences
considering efficacy, expenses, and mechanism of action
(which will be discussed later). However, because these
two agents (Tachosil and glaubran 2) are relatively new,
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there is no study evaluating and comparing the efficacy
of these three hemostatic agents in liver resection, and
there are many controversies about the ideal agent for liver
haemostasis right now.We aim to compare intraoperative and
postoperative findings in patients undergoing liver resection
using TachoSil, Surgicel, or Glubran 2. We used these three
agents because of their availability in our center and different
mechanisms of action.
2. Methods
2.1. Study Population. In this randomized clinical trial, 45
patients (18–75 years old) undergoing liver resection for
any underlying disease and with resectable mass in Imam
Reza Hospital, Tabriz, Iran, during a six-month period from
January 2012 till January 2013 were randomly assigned to
receive application of cyanoacrylate glue (Glubran 2, GEM
S.R.L., Viareggio, Italy) in the aerosol form or be treated
by TachoSil (TachoSil, Takeda Pharmaceuticals International
GmbH, Zurich, Switzerland) or Surgicel (Surgicel, Ethicon
Inc., a Johnson’s and Johnson’s company). Operability of the
patients was fully evaluated before procedure by abdominal
triphasic computed tomographic (CT) scan, Duplex ultra-
sonography of liver vessels, chest X-rays, and chest or brain
CT scans when indicated. Patients were randomly assigned
to these 3 groups by a web-based calculator available in
this web address: http://www.randomizer.org. Randomiza-
tion was continued till the number of patients in each group
reached 15. We could not increase the number of our patients
because of the invasive nature of these procedures, and also it
was the first time that Glubran 2 was used in liver resection
procedure.
2.2. Haemostatic Agents. Glubran 2 is a synthetic surgical
glue, Communaute´ Europe´enne (CE) certificated for internal
and external use, with haemostatic, adhesive, sealer, and
bacteriostatic properties. When used in moist environment,
it quickly polymerizes into a thin elastic film which has high
tensile strength and firmly adheres to the anatomy of the
tissue on which it is applied. Once it is polymerized, Glubran
2 acts as a bioinert material. We used 1 package of 1mL
Glubran 2 for each patient.
TachoSil, a sterile, ready-to-use, absorbable surgical patch
consisting of an equine collagen sponge coated with human
fibrinogen and human thrombin measuring 9.5 × 4.8 ×
0.5 cm, was applied on the resection surfaces after being
moistened with physiological saline. The yellow-coated side
(active side) of the patch was held against the resection sur-
face for 3 minutes to ensure uniform contact. The resection
site(s) had to be covered ≥1 cm beyond its margin, and if >1
patch was needed, they had to overlap. We used only one
package of TachoSil for each patient.
Surgicel absorbable hemostat is a sterile absorbable knit-
ted fabric prepared by the controlled oxidation of regenerated
cellulose. The fabric is white with a pale yellow cast and has
a faint caramel-like aroma. It is strong and can be sutured or
cut without fraying. After Surgicel has been saturated with
blood, it swells into a brownish or black gelatinous mass
which aids in the formation of a clot, thereby serving as
a haemostatic adjunct in the control of local hemorrhage.
When used properly in minimal amounts, Surgicel hemostat
is absorbed from sites of implantation with practically no
tissue reaction. In this study, a 10 × 10 cm product was used
for each patient.
2.3. Resection Method and Inclusion and Exclusion Criteria.
All patients with resectable liver lesions of any size during
this period were included in this study. Liver resection
were done by “clamp and sew” technique following the
anatomic cut surfaces without the use of any specialized liver
cutting system such asWaterjet systems. Patients with oozing
from the resection site despite proper homeostasis effort
(ligation, suture ligation, argon beam coagulation, or electro-
cauterization) were included. Patients with chronic liver
disease, coagulopathy not corrected with treatment before
the surgery, death during surgery, operation discontinuation
due to severe acidosis or coagulopathy, acute liver failure
diagnosed with severe acidosis, and severe uncontrolled INR
were excluded. Patients in need of resurgery due to bleeding
or bile leak from liver other than resection site were also
excluded.
2.4. Ethical Issues. This clinical trial was approved by the
Ethics Committee of Tabriz University of Medical Sciences,
Tabriz, Iran, and was also registered in the Iranian Registry
of Clinical Trials, and informedwritten consent was obtained
from each patient before surgery.
2.5. Objectives. Theprimary objectivewas to compare time to
hemostasis between groups.The largest resection area (target
wound) was assessed for time to hemostasis. Hemostasis
was achieved when there was no visible bleeding from the
resection wound. Counting the time to hemostasis began
when TachoSil, Surgicel, or Glubran 2 was applied. Another
treatmentmethod was used or repeated if hemostasis was not
achieved after 5 minutes.
Secondary end points were evaluatedwith special empha-
sis on the total drainage volume through the Jackson-Pratt
drains (which were inserted at the end of operation in the
resection site), the total postoperative duration of drainage,
the measurement of total volume of transfused blood prod-
ucts, and also by abdominal ultrasonography 2 days after
operation. The operative and clamping techniques used,
segments resected, and hemostatic measures were recorded.
Blood loss was calculated by recording the blood substitute
administered and total number of sponges used and total
amount of blood in the suctions.
Age, gender, type of hepatectomy, operation time, oper-
ative blood loss, and postoperative complications (bleeding,
bile leakage, and wound infection) were compared in the
three groups.
2.6. Blinding. Blinding for surgeons was not possible owing
to the nature of the used materials’ consistency (spongy
TachoSil knitted fabric Surgicel and liquid Glubran 2) and
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Table 1: Indications for liver resections.
TachoSil
(𝑛 = 15)
Surgicel
(𝑛 = 15)
Glubran 2
(𝑛 = 15)
Hepatocellular carcinoma 3 1 2
Hilar cholangiocarcinoma 1 2 0
Adrenal cancer metastasis 1 0 0
Breast cancer metastasis 1 0 0
Colorectal metastasis 1 1 2
Biliary carcinoma 1 1 2
Hemangioma 3 3 3
Hepatic adenoma 2 2 2
Focal nodular hyperplasia 2 2 1
Unilocular hydatid cyst 2 1 0
Multilocular hydatid cyst 0 1 2
Table 2: Baseline findings between groups.
TachoSil
(𝑛 = 15)
Surgicel
(𝑛 = 15)
Glubran 2
(𝑛 = 15) 𝑃 value
Age (years) 45.73±12.20 46.60±12.93 50.86±10.47 NS
Gender
Male 5 (33.3%) 6 (40%) 7 (46.7%) NS
Female 10 (66.7%) 9 (60%) 8 (53.3%)
Hemoglobin
(mg/dL) 12.40 ± 0.68 12.45 ± 1.40 13.11 ± 1.67 NS
NS: not significant.
their packages. The postoperative assessors were completely
blinded to which agents were used for each patient.
2.7. Data Analysis. All data were analyzed using SPSS sta-
tistical package version 16.0 (SPSS Inc. Chicago, IL, USA).
Continuous data with normal distribution are given as
mean ± standard deviation, otherwise as median. Categorical
variables were compared by 𝑥2.
The given data were compared between groups using
one-way ANOVA. Student’s 𝑡-test was used for comparisons
between groups in pair. A 𝑃 value of 0.05 or less was
considered significant.
3. Results
In this study, 45 patients undergoing liver resection were
randomly assigned to receive TachoSil (𝑛 = 15), Surgicel
(𝑛 = 15), and Glubran 2 (𝑛 = 15) for controlling oozing at the
end of the surgery. Indications for liver resections are shown
in Table 1. Hemangioma and hepatocellular carcinomas were
the most common causes for liver resection. There were 3
cases of hilar cholangiocarcinoma, which underwent right
hepatectomy in TachoSil group and left hepatectomy in
Surgicel group.
Table 2 demonstrates baseline findings between groups.
Patients were matched for demographic findings. There was
also no difference between groups in hemoglobin levels
before surgery.
Intraoperative and in-hospital findings are shown in
Table 3. There was no significant difference between groups
and in two-by-two evaluation in intraoperative findings
(𝑃 = NS), but in bleeding rate after homeostasis. In two by
two evaluation, the difference was significant only between
TachoSil and Surgicel groups (𝑃 = 0.04). During postsurgery
admission, there were significant differences between groups
in mean blood drainage volume in the first day after surgery.
Surgicel group had significantly higher first day drainage
volume in comparison to TachoSil (𝑃 = 0.02), but the
difference between Glubran 2 with Surgicel and TachoSil was
not significant (𝑃 = NS).
Bile leakage occurred in 5 cases including one in each
group which was managed with percutaneous drainage
(Table 3); one minor leakage (less than 100mL/day) in Sur-
gicel patients was resolved with the drain implanted during
surgery in three days. All leakage occurred in caseswith left or
right hepatectomy.Therewas also onemajor bile leakage with
more than 500mL/day in a patient with segmentectomy in
Surgicel group which was managed with sphincterotomy by
endoscopic retrograde cholangiopancreatography (ERCP).
FFP was transfused during postoperative period because
of coagulopathy only in one patient (6.7%) in TachoSil group.
The patient had undergone right hepatectomy because of
metastasis from colorectal cancer.
Resurgery due to bleeding from the liver resection sitewas
not needed in any of the cases. Noninfectious collection was
also observed in 5 patients during control ultrasonography,
including one left hepatectomy in Glubran 2 group, one
left hepatectomy and one segmentectomy in Surgicel, and
one right hepatectomy and one segmentectomy in TachoSil
group. These were managed conservatively.
There were also two major complications in Surgicel
group; perihepatic abscess (defined by frank pussy aspirate,
positive bacterial culture, and patient’s fever) in a patient who
underwent segmentectomy was managed with percutaneous
drainage.Therewas also amassive hematoma (750 cc) around
hepatectomy site in a case with right hepatectomy that was
not drained with the implanted drain and was managed with
percutaneous drainage two weeks later.
Mean hospital stay was 7.46±2.79 in TachoSil, 8.13±3.35
in Surgicel, and 8.80±3.50 in Glubran 2 group.The difference
was not significant between the groups (𝑃 = NS).
4. Discussion
TachoSil has beenused in different surgeries, and its efficacy is
well established [11]. Surgicel is a cellulose based hemostatic
agent which is used in controlling minor bleedings such as
oozing from liver or lung cut surfaces with acceptable efficacy
[11].The other product is Glubran 2, an n-butyl cyanoacrylate
glue with high evidence of safety and efficacy in experimental
and laboratory studies [14, 15] as well as in some surgeries
[12, 13]. However, it has not been evaluated for hemostatic
purposes after liver resection. This study is the first study
evaluating the efficacy of these three agents in controlling
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Table 3: Intraoperative and in-hospital findings between groups.
TachoSil Surgicel Glubran 2 P value
Intraoperative bleeding (mL) 766.66 ± 416.90 573.33 ± 281.49 653.33 ± 448.19 0.4
FFP during surgery 0 0.53 ± 0.36 0.80 ± 0.42 0.21
Total transfused packed cell during surgery (units) 4.33 ± 1.07 1.86 ± 0.92 2.13 ± 0.55 0.1
Time to homeostasis 3.00 ± 0.84 3.26 ± 1.48 2.66 ± 1.15 0.43
Suction volume (mL) after hemostasis 89.33 ± 57.37 116.66 ± 52.32 122.66 ± 57.25 0.22
4 × 4 Gauze pads used after hemostasis 3.06 ± 0.70 3.40 ± 1.12 3.25 ± 0.75 0.59
Abdominal pads used after hemostasis 0.80 ± 0.22 1.13 ± 0.23 1.16 ± 0.29 0.51
Bleeding after homeostasis 0 5 (33.3%) 2 (13.3%) 0.004∗
First day drainage 150.00 ± 60.82 281.33 ± 103.98 234.66 ± 187.95 0.02∗
Second day drainage 66.66 ± 25.19 92.00 ± 28.58 75.33 ± 22.76 0.77
Third day drainage 10.66 ± 4.62 5.33 ± 2.36 18.00 ± 7.63 0.25
Time to extract the drain (day) 3.66 ± 0.97 4.06 ± 0.70 5.26 ± 2.89 0.06
Bile leak 1 (6.7%) 3 (20%) 1 (6.7%) 0.4
Packed cell during hospitalization (units) 5 (33.3%) 4 (26.7%) 2 (13.30%) 0.6
∗P is two sided significant. FFP: fresh frozen plasma.
bleeding after liver resection. We used time to hemostasis
as the primary end point and postoperative bleeding, bile
leakage, collections, and infections as the secondary end
points for comparing the efficacy of these three agents. Our
observations show relatively better results for TachoSil in
comparison to Surgicel and Glubran 2, but the difference
was not statistically significant, and the statistical power of
our results was too low because of the small sample size
due to our limitations. Postoperative complications were
most possible to be seen in Surgicel with less incidence in
TachoSil group, although the difference between groups was
not significant.
Bricen˜o et al. [3] observed a better result in case of using
TachoSil; surgeries using TachoSil had less drainage volume,
less transfusion, less moderate to severe complications, and
lower hospital stay in comparison to groups that did not
receive TachoSil.
In a study on bovine, Taka´cs et al. [16] observed less time
to hemostasis in TachoSil in comparison to Surgicel. In our
study, bleeding after hemostasis and mean first postoperative
day blood drainage volume in TachoSil were significantly
lower than Surgicel. However, Zacharias and Ferreira [17]
found a similar complication rate and mean hospital stay in
TachoSil and Surgicel groups; however, TachoSil group had a
little higher hospital stay and less major complications. This
study did not recognize any of them superior to the other.
In our study, hospital stay in TachoSil group was lower than
Surgicel.
In the only study evaluating cyanoacrylate products and
Surgicel in twelve sheep, Ellman et al. [18] observed better
efficacy for cyanoacrylate products.
There are some case reports about complications due to
Surgicel use including granuloma, foreign body reaction, and
neurologic complications [11], as well as abscess [19]. In this
study, complications in Surgicel group were bile leak in 3
cases, noninfectious collection in 2 cases, and perihepatic
abscess and massive hematoma around hepatectomy site
each in one patient. In our opinion, lower biocompatibility
of Surgicel compared with TachoSil will result in delayed
absorption of this cellulose containing material and its future
infectious and inflammatory complication. The higher rate
of complications in Surgicel use questions its applicability in
liver resection.
Despite better results in TachoSil and higher compli-
cations in Surgicel group, overall, the differences between
groups were not significant, and none of them has any
significant superiority to others. However, it is important
to consider the expenses and cost of each agent before
choosing one of them as hemostatic agent. In our study, all
these product were purchased from local distributors. Each
products price was as follows: Surgicel (10 × 10 cm) 34US$,
TachoSil (9.5 × 4.8 × 0.5 cm) 145US$, and Glubran 2 (1mL)
270US$. We used only one package of each of these agents
for each patient.
Glubran 2 is the most expensive topical agent with
no significantly better efficacy, and Surgicel has higher
complications unlike its lower price. Considering better
results of TachoSil, it is possible to consider TachoSil as
the best option for hemostasis control after liver resec-
tion; however, further studies are needed to confirm these
findings because of our small group and diversity of our
patients (segmental versus major hepatectomies, malignant
versus benign conditions, and long versus short time oper-
ations). We use hemostatic agents only when oozing after
mechanical hemostasis continues. Many times, we do not
need any of these agents for hemostasis if we follow strict
anatomical plains for liver resection. We have performed
49 liver resections in the same period without the need
of any hemostatic agents. In our experience, none of these
hemostatic agents could be used for stopping major bleeding
from liver vasculature especially in trauma patients. Due
to our inclusion criteria (continuous oozing after surgi-
cal hemostasis), we did not include these patients in our
study.
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5. Conclusion
The results of the current study are indicative of slight differ-
ences in hemostasis control of TachoSil, Surgicel, and Glu-
bran 2. Due to higher complications in Surgicel group,
although, less expensive than the other two agents, its appli-
cation as a hemostatic agent after liver resection is not recom-
mended. Better results in TachoSil in comparison to the other
two are indicative of its better efficacy and superiority in
controlling hemostasis.
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